Eloxx Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2017 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Eloxx Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2017 to Q3 2023.
  • Eloxx Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2023 was $418K, a 41.5% decline year-over-year.
  • Eloxx Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2023 was $2.4M, a 25.9% decline year-over-year.
  • Eloxx Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3.02M, a 67% decline from 2021.
  • Eloxx Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $9.17M, a 5.78% increase from 2020.
  • Eloxx Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2020 was $8.67M, a 23.6% decline from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 $2.4M $418K -$296K -41.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $2.7M $610* -$134 -18% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-11
Q1 2023 $2.7M $597K -$325K -35.2% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-12
Q4 2022 $3.02M $1.38M -$216K -13.5% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-31
Q3 2022 $3.24M $714K -$1.51M -67.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $4.75M $744* -$4.03M -100% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 $8.78M $922K -$386K -29.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 $9.17M $1.6M +$319K +24.9% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 $8.85M $2.22M +$810K +57.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $8.04M $4.04M +$2.06M +104% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 $5.98M $1.31M -$2.69M -67.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 $8.67M $1.28M -$1.42M -52.6% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-30
Q3 2020 $10.1M $1.41M -$1.54M -52.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $11.6M $1.98M -$1.04M -34.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 $12.7M $4M +$1.34M +50.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 $11.3M $2.71M -$1.06M -28.1% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-30
Q3 2019 $12.4M $2.96M +$262K +9.72% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 $12.1M $3.02M -$3.16M -51.2% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 $15.3M $2.66M +$1.92M +262% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 $13.4M $3.76M +$3.7M +5968% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-12
Q3 2018 $9.67M $2.7M +$2.68M +15753% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 $6.99M $6.18M +$6.17M +56064% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $825K $735K +$724K +6582% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $101K $62K Oct 1, 2017 Dec 31, 2017 10-K 2020-03-06
Q3 2017 $17K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $11K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-10
Q1 2017 $11K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.